NCT02924155已完成1 期
A Randomized, Double-blind, Placebo-controlled, Single Day/Multiple Day Dosing, Phase I Clinical Trial to Investigate the Systemic Exposure, Safety and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Korean Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Incidence of Treatment Emergent Adverse Event(TEAE)
研究概览
简要总结
This is a phase1, single center, double-blind, placebo control, randomized study and consisted of single dosing(period 1) and multiple dosing(period 2).
In this clinical trial, safety and local tolerability are evaluated for 7 days after single dosing of the investigational product. If multiple dosing is judged to be acceptable as a result of single dosing evaluation (safety and local tolerability evaluation including ophthalmic examination), multiple dosing starts from Day 8(7 days after the single dosing) for 14 days. Safety and local tolerability, including ophthalmic symptom assessment, should be evaluated during the multiple dosing period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subject who voluntarily agrees to participate in this study and has given a written informed consent, after fully understanding the detailed explanation of this study
- •20 years to 50 years (Healthy male Korean)
排除标准
- •Subject with a disease history of any clinically significant condition as below.
- •Liver, Kidney, nervous system, immune system, respiratory system, endocrine system, tumor, cardiovascular disease or mental illness (mood disorder or obsessive-compulsive disorder etc.) etc.
- •Subject with a history of clinically significant hypersensitivity or hypersensitivity reactions to drugs (aspirin, antibiotics, etc.)
- •Subject with a disease history of any ophthalmic condition as below
- •History of or suspected symptoms or signs of vision problems, including keratitis, uveitis, retinitis, dry eye syndrome, and strabismus.
- •Corrected eyesight measured at screening is 20/40 or less
- •Those who have previously had ophthalmic surgery. (Exceptional case: in the case of having ophthalmic laser surgery before 6 months from the screening)
- •Those who have experienced side effects after wearing contact lenses, those who have worn contact lenses within the last month, or those who cannot ban wearing contact lens during the clinical trial
- •Abnormal findings in other ophthalmic examinations
- •Subject with a history of drug abuse or who is positive for drugs of abuse in urine tests at screening
- •Subject who received any drugs such as
- •Prescription drug or herbal medicine within 14 days prior to the first administration of the investigational products
- •Over the counter (OTC) or vitamin within 7 days prior to the first administration of the investigational products
- •Subject who received other investigational products within 90 days prior to the first administration of the investigational products
- •Subject who have donated whole blood within 60 days prior to the first administration of the investigational products, or donated component blood or have received blood transfusion within 30 days prior to the first administration of the investigational products
- •Subject who continuously drink alcohol (more than 21 units/week, 1 unit = 10 g of pure alcohol) or cannot abstain from alcohol during the study period
- •Subject who smoked more than 10 cigarettes a day on average in the last 90 days, and who cannot quit smoking during hospitalization
- •Man of reproductive potential not willing to use contraceptive measures during the study period
- •Subject not eligible for study participation in the opinion of the investigator
研究组 & 干预措施
SJP002
Experimental
9 subjects received single dose of SJP002 and then received multiple dose of SJP002
干预措施: SJP002 (Drug)
Placebo
Placebo Comparator
3 subjects received single dose of placebo and then received multiple dose of placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence of Treatment Emergent Adverse Event(TEAE)
时间窗: Day 1(administration) to approximately Day 37(Post study visit)
Safety/Tolerability Assessment
次要结局
- Measure the Peak Plasma Concentration (Cmax) of SJP002(Period 1: Day2(predose and 0.5~24 hours postdose))
- Measure the Area Under the plasma concentration versus time Curve from the first observed to last(AUClast) of SJP002(Period 1: Day2(predose and 0.5~24 hours postdose))
- Measure the Area Under the plasma concentration versus time Curve from the first sampled data extrapolated to infinity(AUCinf) of SJP002(Period 1: Day2(predose and 0.5~24 hours postdose))
- Measure the Time to peak drug concentration(Tmax) of SJP002(Period 1: Day2(predose and 0.5~24 hours postdose))
- Measure the Half Life(t1/2) of SJP002(Period 1: Day2(predose and 0.5~24 hours postdose))
- Measure the Trough Drug Concentration at steady state(Cmin,ss) of SJP002(Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose))
- Measure the Area Under the plasma concentration-time Curve over a dosing interval at steady state(AUCtau,ss) of SJP002(Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose))
- Measure the Time to peak drug concentration at steady state(Tmax,ss) of SJP002(Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose))
- Measure the Half Life at steady state(T1/2,ss) of SJP002(Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose))
- Measure the Peak Plasma Concentration Accumulation Ratio (RA,Cmax) of SJP002(Period 2: Day10(predose), Day23(predose and 0.5~24 hours postdose))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase I Study of SB26 in Healthy VolunteersHealthy VolunteersNCT03630627Samsung Bioepis Co., Ltd.58
已完成
1 期
Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy VolunteersHealthy SubjectsNCT05201690Vigonvita Life Sciences36
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult ParticipantsNon-alcoholic SteatohepatitisNCT06716905Xiamen Amoytop Biotech Co., Ltd.72
已完成
1 期
A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult SubjectsHealthyNCT04976270Galapagos NV23
已完成
1 期
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese ParticipantsHealthy VolunteersNCT04138043GlaxoSmithKline9